TETSUO ASHIZAWA to Mice
This is a "connection" page, showing publications TETSUO ASHIZAWA has written about Mice.
Connection Strength
0.226
-
DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases. Neurotherapeutics. 2021 07; 18(3):1710-1728.
Score: 0.053
-
Transgenic mice with SCA10 pentanucleotide repeats show motor phenotype and susceptibility to seizure: a toxic RNA gain-of-function model. J Neurosci Res. 2012 Mar; 90(3):706-14.
Score: 0.027
-
The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology. 2006 Aug 22; 67(4):607-13.
Score: 0.019
-
Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet. 2000 Oct; 26(2):191-4.
Score: 0.013
-
Deficiency in classical nonhomologous end-joining-mediated repair of transcribed genes is linked to SCA3 pathogenesis. Proc Natl Acad Sci U S A. 2020 04 07; 117(14):8154-8165.
Score: 0.012
-
SCA8 RAN polySer protein preferentially accumulates in white matter regions and is regulated by eIF3F. EMBO J. 2018 10 01; 37(19).
Score: 0.011
-
Antitumor activity of KW-2170, a novel pyrazoloacridone derivative. Anticancer Drugs. 1998 Mar; 9(3):263-71.
Score: 0.011
-
ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. Ann Neurol. 2016 10; 80(4):600-15.
Score: 0.010
-
Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy. Mol Ther. 2016 08; 24(8):1378-87.
Score: 0.009
-
Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice. Anticancer Drugs. 1995 Dec; 6(6):763-70.
Score: 0.009
-
The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis. PLoS Genet. 2015 Jan; 11(1):e1004749.
Score: 0.008
-
Mapping of the polypeptide chain organization of the main extracellular domain of the alpha-subunit in membrane-bound acetylcholine receptor by antipeptide antibodies spanning the entire domain. Adv Exp Med Biol. 1994; 347:221-8.
Score: 0.008
-
Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron. 2012 Aug 09; 75(3):437-50.
Score: 0.007
-
Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):5852-6.
Score: 0.007
-
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012 Jan 26; 1(1):2-12.
Score: 0.007
-
Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity. 2002 May; 35(3):183-90.
Score: 0.004
-
Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J Neuroimmunol. 2000 Jun 26; 105(2):131-44.
Score: 0.003
-
Genetic localization of the Ca2+ channel gene CACNG2 near SCA10 on chromosome 22q13. Epilepsia. 2000 Jan; 41(1):24-7.
Score: 0.003
-
Analysis of exposed regions on the main extracellular domain of mouse acetylcholine receptor alpha subunit in live muscle cells by binding profiles of antipeptide antibodies. J Protein Chem. 1994 Nov; 13(8):715-22.
Score: 0.002
-
Properties of nine continuous B-cell lines established from enzootic bovine leukosis tumors. Zentralbl Veterinarmed B. 1992 Feb; 39(1):32-8.
Score: 0.002
-
Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action. Cancer Chemother Pharmacol. 1992; 29(4):266-72.
Score: 0.002